University of the Witwatersrand, Johannesburg, South Africa.
Division of Nephrology, Helen Joseph Hospital, Johannesburg, South Africa.
BMC Psychol. 2023 May 8;11(1):151. doi: 10.1186/s40359-023-01196-1.
Mental health and quality of life are under-appreciated clinical targets which affect patient and modality survival. Lack of dialysis availability in the resource-constrained public health sector in South Africa results in assignment to treatment modalities without regard to effects on these parameters. We assessed the effect of dialysis modality, demographic and laboratory parameters on mental health and quality of life measurements.
Size-matched cohorts were recruited from patients on haemodialysis (HD), peritoneal dialysis (PD), and patients on conservative management (CM) between September 2020 and March 2021. Responses to the Hospital Anxiety and Depression Scale (HADS) and Kidney Disease Quality of Life Short Form 36 (KDQOL-SF36) questionnaires and demographic and baseline laboratory parameters were compared between modalities. Multivariate linear regression was used to evaluate independent effect of baseline characteristics on HADS and KDQOL-SF36 scores between treatment groups where significant difference was observed.
Anxiety, depression, and reduced KDQOL measures were widespread amongst respondents. Dialyzed patients reported higher anxiety and depression scores than those on CM (p = 0.040 and p = 0.028). Physical composite (PCS), role-physical (RP), vitality (VS), and emotional well-being (EWB) KDQOL-SF36 scores were poorer in dialyzed patients (p < 0.001 for all). PCS (p = 0.005), pain (p = 0.030), vitality (p = 0.005), and social functioning KDQOL scores were poorer in PD compared to HD; HADS anxiety (p < 0.001) and KDQOL-SF36 EWB scores (p < 0.001) were better in PD. PD patients were more likely to be employed (p = 0.008). Increasing haemoglobin concentration reduced anxiety (p < 0.001) and depression scores (p = 0.004), and improved PCS (p < 0.001), and pain scores (p < 0.001). Higher serum albumin improved PCS (p < 0.001) and vitality (p < 0.001) scores.
Advanced chronic kidney disease increases anxiety and depression and limits quality of life. PD improves mental health and emotional wellbeing and preserves the ability to undertake economic activity but limits social functioning and causes greater physical discomfort. Targeting haemoglobin may ameliorate modality effects on mental health and quality of life.
心理健康和生活质量是被低估的临床指标,它们会影响患者和治疗方式的存活率。在南非资源有限的公共卫生部门,缺乏透析机会导致治疗方式的选择不考虑这些参数的影响。我们评估了透析方式、人口统计学和实验室参数对心理健康和生活质量测量的影响。
在 2020 年 9 月至 2021 年 3 月期间,我们从血液透析(HD)、腹膜透析(PD)和保守治疗(CM)的患者中招募了匹配大小的队列。比较了不同治疗方式患者的医院焦虑和抑郁量表(HADS)和肾脏病生活质量简表 36 项(KDQOL-SF36)问卷的反应以及人口统计学和基线实验室参数。在观察到显著差异的情况下,使用多元线性回归评估了基线特征对治疗组中 HADS 和 KDQOL-SF36 评分的独立影响。
焦虑、抑郁和降低的 KDQOL 测量结果在受访者中普遍存在。与 CM 组相比,透析患者报告的焦虑和抑郁评分更高(p=0.040 和 p=0.028)。PD 患者的生理综合评分(PCS)、角色生理(RP)、活力(VS)和情感健康(EWB)KDQOL-SF36 评分更差(所有 p<0.001)。与 HD 相比,PD 患者的 PCS(p=0.005)、疼痛(p=0.030)、活力(p=0.005)和社会功能 KDQOL 评分更差;PD 患者的 HADS 焦虑评分(p<0.001)和 KDQOL-SF36 EWB 评分(p<0.001)更好。PD 患者更有可能就业(p=0.008)。血红蛋白浓度增加可降低焦虑(p<0.001)和抑郁评分(p=0.004),并改善 PCS(p<0.001)和疼痛评分(p<0.001)。更高的血清白蛋白可改善 PCS(p<0.001)和活力(p<0.001)评分。
晚期慢性肾脏病会增加焦虑和抑郁,并限制生活质量。PD 改善心理健康和情感健康,保持从事经济活动的能力,但限制社会功能并引起更大的身体不适。针对血红蛋白可能会改善治疗方式对心理健康和生活质量的影响。